<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/><meta name="exporter-version" content="Evernote Mac 7.14 (458244)"/><meta name="author" content="taylor.arhar@gmail.com"/><meta name="created" content="2019-06-14 18:20:27 +0000"/><meta name="source" content="desktop.mac"/><meta name="updated" content="2019-06-21 22:46:35 +0000"/><title>May 22, 2019</title></head><body><div>DJA1 purification day 2:</div><div>- GOALS: reverse purify away the TEV, then isolate dimeric, non aggregated DJA1 by SEC200</div><div>- after equilibrating Ni-NTA resin in wash 1 buffer, samples were incubated with resin for 1hr at 4C with rocking</div><div>- flowthrough and elutions were assessed by SDS-PAGE (see attached)</div><div>- flowthrough fractions were concentrated to ~15mL total, and 5mL of was injected onto pre-equilibrated SEC200 column (see attached SEC200 trace)</div><div>- RESULTS: (1) the high amount of DJA1 present in the elution fraction suggests a low activity of this batch of TEV; (2) almost all of the DJA1 injected onto the SEC200 column eluted in the void fraction, suggesting extensive aggregation; due to this aggregation, the purified protein was discarded</div><div><img src="May%2022,%202019.html.resources/2019-05-22%2014h13m27s%20Coomassie%20Blue(Coomassie%20Blue).tif" >DJA1 SEC200 052219.pdf</a><br/></div><div><br/></div><div><br/></div></body></html>
